{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:18:57Z","timestamp":1790702337451,"version":"4.1.0"},"reference-count":149,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002803","name":"Fondazione Cariplo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002803","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.atherosclerosis.2019.07.015","type":"journal-article","created":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T19:43:31Z","timestamp":1563392611000},"page":"146-155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":121,"special_numbering":"C","title":["PCSK9 inhibition and inflammation: A narrative review"],"prefix":"10.1016","volume":"288","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0195-7061","authenticated-orcid":false,"given":"Massimiliano","family":"Ruscica","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lale","family":"Tokg\u00f6zo\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Corsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare R.","family":"Sirtori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib1","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1177\/2047487317695628","article-title":"The impact of medication adherence on clinical outcomes of coronary artery disease: a meta-analysis","volume":"24","author":"Du","year":"2017","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib2","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1161\/CIRCULATIONAHA.116.021314","article-title":"Distribution of estimated 10-year risk of recurrent vascular events and residual risk in a secondary prevention population","volume":"134","author":"Kaasenbrood","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib3","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.005077","article-title":"Inflammatory biomarkers interleukin-6 and C-reactive protein and outcomes in stable coronary heart disease: experiences from the STABILITY (stabilization of atherosclerotic plaque by initiation of darapladib therapy) trial","volume":"6","author":"Held","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib4","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib5","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib6","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1001\/jama.285.19.2481","article-title":"Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease","volume":"285","author":"Ridker","year":"2001","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib7","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/eurheartj\/ehw024","article-title":"Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin","volume":"37","author":"Ridker","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0049-0172(05)80003-4","article-title":"The value of C-reactive protein measurement in rheumatoid arthritis","volume":"24","author":"Otterness","year":"1994","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib9","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1161\/CIRCULATIONAHA.118.035107","article-title":"Low-Grade inflammation modifies cardiovascular risk even at very low LDL-C levels: are we aiming for a dual target concept?","volume":"138","author":"Koenig","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib10","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jacc.2013.05.016","article-title":"High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link?","volume":"62","author":"Yousuf","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"issue":"8","key":"10.1016\/j.atherosclerosis.2019.07.015_bib11","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1177\/2047487319829307","article-title":"Inflammation in coronary artery disease: which biomarker and which treatment?","volume":"26","author":"Gaudino","year":"2019","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib12","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1161\/CIRCULATIONAHA.109.874834","article-title":"Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)","volume":"121","author":"Everett","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib13","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1016\/j.jacc.2007.01.083","article-title":"Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis","volume":"49","author":"Kinlay","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib14","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/eurheartj\/ehy822","article-title":"Haemodynamic stress-induced breaches of the arterial intima trigger inflammation and drive atherogenesis","volume":"40","author":"Franck","year":"2019","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib15","doi-asserted-by":"crossref","first-page":"14871","DOI":"10.1073\/pnas.0406073101","article-title":"Distinct endothelial phenotypes evoked by arterial waveforms derived from atherosclerosis-susceptible and -resistant regions of human vasculature","volume":"101","author":"Dai","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/cvr\/cvx226","article-title":"Endothelial permeability, LDL deposition, and cardiovascular risk factors-a review","volume":"114","author":"Mundi","year":"2018","journal-title":"Cardiovasc. Res."},{"issue":"7","key":"10.1016\/j.atherosclerosis.2019.07.015_bib17","first-page":"389","article-title":"Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities","volume":"16","author":"Back","year":"2019","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.tcm.2019.01.004","article-title":"Inflammation, infection and atherosclerosis","author":"Shah","year":"2019","journal-title":"Trends Cardiovasc. Med."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib19","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMra043430","article-title":"Inflammation, atherosclerosis, and coronary artery disease","volume":"352","author":"Hansson","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib20","doi-asserted-by":"crossref","first-page":"III20","DOI":"10.1161\/01.CIR.0000131514.71167.2e","article-title":"Inflammation in atherosclerosis and implications for therapy","volume":"109","author":"Paoletti","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib21","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.tcm.2018.05.010","article-title":"Oxidized LDL and anti-oxidized LDL antibodies in atherosclerosis - novel insights and future directions in diagnosis and therapy","volume":"29","author":"Hartley","year":"2019","journal-title":"Trends Cardiovasc. Med."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib22","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1146\/annurev.pathol.1.110304.100100","article-title":"Inflammation and atherosclerosis","volume":"1","author":"Hansson","year":"2006","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib23","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.atherosclerosis.2018.07.014","article-title":"Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions","volume":"276","author":"Raggi","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib24","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/nri.2016.63","article-title":"Innate sensing of oxidation-specific epitopes in health and disease","volume":"16","author":"Binder","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib25","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.bbalip.2017.01.006","article-title":"Lipid modification and lipid peroxidation products in innate immunity and inflammation","volume":"1862","author":"Binder","year":"2017","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib26","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1161\/CIRCULATIONAHA.113.005015","article-title":"Contribution of intimal smooth muscle cells to cholesterol accumulation and macrophage-like cells in human atherosclerosis","volume":"129","author":"Allahverdian","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib27","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/MOL.0000000000000574","article-title":"Pathways of smooth muscle foam cell formation in atherosclerosis","volume":"30","author":"Pryma","year":"2019","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib28","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1172\/JCI117195","article-title":"Expression of alpha 2-macroglobulin receptor\/low density lipoprotein receptor-related protein and scavenger receptor in human atherosclerotic lesions","volume":"93","author":"Luoma","year":"1994","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib29","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.immuni.2017.09.008","article-title":"Monocyte-Macrophages and T Cells in atherosclerosis","volume":"47","author":"Tabas","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib30","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/nature08938","article-title":"NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals","volume":"464","author":"Duewell","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib31","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1093\/eurheartj\/ehv653","article-title":"Cholesterol crystal induced arterial inflammation and destabilization of atherosclerotic plaque","volume":"37","author":"Janoudi","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib32","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1161\/CIRCRESAHA.118.311362","article-title":"NLRP3 inflammasome and the IL-1 pathway in atherosclerosis","volume":"122","author":"Grebe","year":"2018","journal-title":"Circ. Res."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib33","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1074-7613(04)00046-9","article-title":"NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder","volume":"20","author":"Agostini","year":"2004","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2019.07.015_bib34","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1194\/jlr.S091280","article-title":"Neutrophil extracellular traps, and cholesterol","volume":"60","author":"Tall","year":"2019","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib35","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jacc.2018.06.046","article-title":"Impact of lipids on cardiovascular health: JACC health promotion series","volume":"72","author":"Ference","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib36","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jama.298.3.299","article-title":"Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women","volume":"298","author":"Nordestgaard","year":"2007","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib37","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1001\/jama.2018.20045","article-title":"Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease","volume":"321","author":"Ference","year":"2019","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib38","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nrcardio.2013.140","article-title":"Demystifying the management of hypertriglyceridaemia","volume":"10","author":"Watts","year":"2013","journal-title":"Nat. Rev. Cardiol."},{"issue":"22","key":"10.1016\/j.atherosclerosis.2019.07.015_bib39","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1016\/j.jacc.2019.02.032","article-title":"Effects of icosapent ethyl on total ischemic events: from REDUCE-IT","volume":"73","author":"Bhatt","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib40","doi-asserted-by":"crossref","first-page":"462","DOI":"10.5551\/jat.RV17003","article-title":"PCSK9 and atherosclerosis - lipids and beyond","volume":"24","author":"Shapiro","year":"2017","journal-title":"J. Atheroscler. Thromb."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2019.07.015_bib41","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1089\/ars.2014.6054","article-title":"Hemodynamic shear stress via ROS modulates PCSK9 expression in human vascular endothelial and smooth muscle cells and along the mouse aorta","volume":"22","author":"Ding","year":"2015","journal-title":"Antioxid Redox Signal"},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib42","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.atherosclerosis.2011.11.026","article-title":"Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels","volume":"220","author":"Ferri","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib43","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.febslet.2013.02.027","article-title":"Proprotein convertase subtilisin\/kexin type 9 potentially influences cholesterol uptake in macrophages and reverse cholesterol transport","volume":"587","author":"Shen","year":"2013","journal-title":"FEBS Lett."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib44","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.atherosclerosis.2015.09.008","article-title":"A systematic literature review of the effect of carotid atherosclerosis on local vessel stiffness and elasticity","volume":"243","author":"Boesen","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib45","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jacl.2018.02.004","article-title":"Improved endothelial function after short-term therapy with evolocumab","volume":"12","author":"Maulucci","year":"2018","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib46","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.numecd.2019.01.010","article-title":"Improvement in arterial stiffness after short-term treatment with PCSK9 inhibitors","volume":"29","author":"Cicero","year":"2019","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib47","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/cvr\/cvw053","article-title":"Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms","volume":"110","author":"Tavori","year":"2016","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib48","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/path.4630","article-title":"Local effects of human PCSK9 on the atherosclerotic lesion","volume":"238","author":"Giunzioni","year":"2016","journal-title":"J. Pathol."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib49","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.atherosclerosis.2016.07.910","article-title":"PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement","volume":"253","author":"Ferri","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib50","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.atherosclerosis.2016.03.010","article-title":"PCSK9 in relation to coronary plaque inflammation: results of the ATHEROREMO-IVUS study","volume":"248","author":"Cheng","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib51","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1194\/jlr.M078360","article-title":"PCSK9 deficiency reduces atherosclerosis, apolipoprotein B secretion, and endothelial dysfunction","volume":"59","author":"Sun","year":"2018","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2016.11.019","article-title":"Inhibitory effect of PCSK9 on Abca1 protein expression and cholesterol efflux in macrophages","volume":"256","author":"Adorni","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib53","doi-asserted-by":"crossref","DOI":"10.1111\/joim.12758","article-title":"PCSK9 plays a novel immunological role in oxidized LDL-induced dendritic cell maturation and activation of T cells from human blood and atherosclerotic plaque","author":"Liu","year":"2018","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib54","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.atherosclerosis.2017.04.023","article-title":"New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4\/NF-kappaB pathway","volume":"262","author":"Tang","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib55","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1038\/s41598-018-20425-x","article-title":"PCSK9 induces a pro-inflammatory response in macrophages","volume":"8","author":"Ricci","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib56","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/cvr\/cvv178","article-title":"Cross-talk between LOX-1 and PCSK9 in vascular tissues","volume":"107","author":"Ding","year":"2015","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib57","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/cvr\/cvy079","article-title":"PCSK9 regulates expression of scavenger receptors and ox-LDL uptake in macrophages","volume":"114","author":"Ding","year":"2018","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib58","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1194\/jlr.M051326","article-title":"Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin","volume":"55","author":"Kuhnast","year":"2014","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib59","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1093\/eurheartj\/ehx260","article-title":"The AT04A vaccine against proprotein convertase subtilisin\/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice","volume":"38","author":"Landlinger","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib60","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1093\/eurheartj\/ehx002","article-title":"PCSK9 monoclonal antibodies reverse the pro-inflammatory profile of monocytes in familial hypercholesterolaemia","volume":"38","author":"Bernelot Moens","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib61","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrcardio.2017.75","article-title":"PCSK9 inhibitors and foamy monocytes in familial hypercholesterolaemia","volume":"14","author":"Wu","year":"2017","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib62","article-title":"Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin\/kexin type 9 antibody treatment","author":"Stiekema","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib63","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1093\/cvr\/cvx224","article-title":"CCR2 expression on circulating monocytes is associated with arterial wall inflammation assessed by 18F-FDG PET\/CT in patients at risk for cardiovascular disease","volume":"114","author":"Verweij","year":"2018","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib64","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1093\/eurheartj\/ehy385","article-title":"Lipoprotein(a): the perpetual supporting actor","volume":"39","author":"Gencer","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib65","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.atherosclerosis.2019.07.015_bib66","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/s41569-018-0153-2","article-title":"Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease","volume":"16","author":"Boffa","year":"2019","journal-title":"Nat. Rev. Cardiol."},{"issue":"12","key":"10.1016\/j.atherosclerosis.2019.07.015_bib67","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition and cardiovascular risk: Insights from the FOURIER trial","volume":"139","author":"O\u2019Donoghue","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib68","doi-asserted-by":"crossref","DOI":"10.1177\/2047487319833504","article-title":"PCSK9 monoclonal antibodies and lipoprotein apheresis for lowering lipoprotein(a): making choices in an era of RNA-based therapies","author":"Ruscica","year":"2019","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib69","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1001\/jama.2009.954","article-title":"Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease","volume":"302","author":"Elliott","year":"2009","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib70","doi-asserted-by":"crossref","first-page":"d548","DOI":"10.1136\/bmj.d548","article-title":"Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data","volume":"342","author":"Collaboration, CRPCHDG","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib71","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/CIRCULATIONAHA.110.948570","article-title":"Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels","volume":"123","author":"Dehghan","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib72","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1093\/eurheartj\/ehy723","article-title":"Has the time finally come to measure hsCRP universally in primary and secondary cardiovascular prevention?","volume":"39","author":"Ridker","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib73","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1056\/NEJMoa032804","article-title":"C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease","volume":"350","author":"Danesh","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib74","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1161\/CIRCRESAHA.114.302770","article-title":"Infusion of pharmaceutical-grade natural human C-reactive protein is not proinflammatory in healthy adult human volunteers","volume":"114","author":"Lane","year":"2014","journal-title":"Circ. Res."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib75","doi-asserted-by":"crossref","first-page":"8309","DOI":"10.1073\/pnas.0503202102","article-title":"Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice","volume":"102","author":"Hirschfield","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib76","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1160\/TH07-10-0595","article-title":"No effect of C-reactive protein on early atherosclerosis in LDLR-\/-\/human C-reactive protein transgenic mice","volume":"99","author":"Torzewski","year":"2008","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib77","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1161\/01.ATV.0000171983.95612.90","article-title":"Role of C-reactive protein in atherogenesis: can the apolipoprotein E knockout mouse provide the answer?","volume":"25","author":"Reifenberg","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib78","doi-asserted-by":"crossref","first-page":"6272","DOI":"10.1074\/jbc.M110.161414","article-title":"No reduction of atherosclerosis in C-reactive protein (CRP)-deficient mice","volume":"286","author":"Teupser","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib79","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2019.0179","article-title":"Association of initial and serial C-reactive protein levels with adverse cardiovascular events and death after acute coronary syndrome: a secondary analysis of the VISTA-16 trial","author":"Mani","year":"2019","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib80","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1161\/ATVBAHA.117.310052","article-title":"Evaluation of the pleiotropic effects of statins: a reanalysis of the randomized trial evidence using egger regression-brief report","volume":"38","author":"Labos","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib81","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.CIR.98.9.839","article-title":"Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators","volume":"98","author":"Ridker","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib82","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(09)60447-5","article-title":"Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial","volume":"373","author":"Ridker","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib83","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib84","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1111\/bph.13805","article-title":"Vascular inflammation and low-density lipoproteins: is cholesterol the link? A lesson from the clinical trials","volume":"174","author":"Catapano","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib85","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.jacc.2005.02.080","article-title":"Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg\/dl and C-reactive protein <2 mg\/l: an analysis of the PROVE-IT TIMI-22 trial","volume":"45","author":"Ridker","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib86","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","article-title":"Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial","volume":"291","author":"Nissen","year":"2004","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib87","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0140-6736(10)62174-5","article-title":"C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study","volume":"377","author":"Heart Protection Study Collaborative","year":"2011","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2019.07.015_bib88","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.116.005934","article-title":"Relationship between serum inflammatory marker levels and the dynamic changes in coronary plaque characteristics after statin therapy","volume":"10","author":"Kwon","year":"2017","journal-title":"Circ. Cardiovasc. Imag."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib89","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/j.jacc.2018.06.078","article-title":"Effect of evolocumab on coronary plaque composition","volume":"72","author":"Nicholls","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib90","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1161\/STROKEAHA.116.013647","article-title":"Combined effects of inflammatory status and carotid atherosclerosis: a 12-year follow-up study","volume":"47","author":"Mayer","year":"2016","journal-title":"Stroke"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2019.07.015_bib91","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1177\/2047487318806985","article-title":"Left main coronary wall thickness correlates with the carotid intima media thickness and may provide a new marker of cardiovascular risk","volume":"26","author":"Ruscica","year":"2019","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib92","first-page":"1600","article-title":"Cardiovascular efficacy and safety of PCSK9 inhibitors: systematic review and meta-analysis including the ODYSSEY OUTCOMES trial","volume":"34","author":"Turgeon","year":"2018","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib93","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006910","article-title":"Effect of PCSK9 inhibitors on clinical outcomes in patients with hypercholesterolemia: a meta-analysis of 35 randomized controlled trials","volume":"6","author":"Karatasakis","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib94","doi-asserted-by":"crossref","DOI":"10.1007\/s40618-019-01019-4","article-title":"Effects of PCSK9 inhibitors on LDL cholesterol, cardiovascular morbidity and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials","author":"Dicembrini","year":"2019","journal-title":"J. Endocrinol. Investig."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib95","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.atherosclerosis.2017.10.022","article-title":"PCSK9 antagonists and inflammation","volume":"268","author":"Ruscica","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib96","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-022348","article-title":"Impact of PCSK9 monoclonal antibodies on circulating hs-CRP levels: a systematic review and meta-analysis of randomised controlled trials","volume":"8","author":"Cao","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib97","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","article-title":"Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial","volume":"9","author":"Moriarty","year":"2015","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib98","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.2012.25790","article-title":"Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial","volume":"308","author":"Sullivan","year":"2012","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib99","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","article-title":"Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab","volume":"63","author":"Stroes","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib100","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","article-title":"Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial","volume":"315","author":"Nissen","year":"2016","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib101","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1161\/CIRCULATIONAHA.118.034645","article-title":"Residual inflammatory risk on treatment with PCSK9 inhibition and statin therapy","volume":"138","author":"Pradhan","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib102","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1074\/jbc.M115.664706","article-title":"Suppressor of cytokine signaling-3 (SOCS-3) induces proprotein convertase subtilisin kexin type 9 (PCSK9) expression in hepatic HepG2 cell line","volume":"291","author":"Ruscica","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib103","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib104","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1161\/CIRCULATIONAHA.118.034032","article-title":"Inflammatory and cholesterol risk in the FOURIER trial","volume":"138","author":"Bohula","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib105","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib106","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehz299","article-title":"Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial","author":"White","year":"2019","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.atherosclerosis.2019.07.015_bib107","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1161\/CIRCULATIONAHA.118.038840","article-title":"Effect of alirocumab on mortality after acute coronary syndromes: An analysis of the odyssey outcomes randomized clinical trial","volume":"140","author":"Steg","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib108","article-title":"Patients with recent acute coronary syndrome and polyvascular disease derive large absolute benefit from alirocumab: ODYSSEY OUTCOMES trial","author":"Jukema","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9","key":"10.1016\/j.atherosclerosis.2019.07.015_bib109","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1177\/2047487319831500","article-title":"Changes in circulating pro-protein convertase subtilisin\/kexin type 9 levels - experimental and clinical approaches with lipid-lowering agents","volume":"26","author":"Macchi","year":"2019","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib110","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib111","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jacc.2018.04.054","article-title":"The evolving future of PCSK9 inhibitors","volume":"72","author":"Rosenson","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib112","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1161\/CIRCULATIONAHA.118.034942","article-title":"Metabolomic consequences of genetic inhibition of PCSK9 compared with statin treatment","volume":"138","author":"Sliz","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib113","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0014-5793(87)80168-0","article-title":"Assignment of resonances for 'acute-phase' glycoproteins in high resolution proton NMR spectra of human blood plasma","volume":"215","author":"Bell","year":"1987","journal-title":"FEBS Lett."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib114","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1161\/CIRCRESAHA.115.308078","article-title":"Circulating N-linked glycoprotein acetyls and longitudinal mortality risk","volume":"118","author":"Lawler","year":"2016","journal-title":"Circ. Res."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib115","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003822","article-title":"Circulating N-linked glycoprotein side-chain biomarker, rosuvastatin therapy, and incident cardiovascular disease: an analysis from the JUPITER trial","volume":"5","author":"Akinkuolie","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib116","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1001\/jamainternmed.2013.3728","article-title":"HIV infection and the risk of acute myocardial infarction","volume":"173","author":"Freiberg","year":"2013","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib117","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jacc.2012.06.063","article-title":"HIV and coronary heart disease: time for a better understanding","volume":"61","author":"Boccara","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib118","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.atherosclerosis.2019.03.002","article-title":"PCSK9 in HIV infection: new opportunity or red herring?","volume":"284","author":"Ruscica","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib119","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1097\/QAD.0000000000001633","article-title":"Impact of protease inhibitors on circulating PCSK9 levels in HIV-infected antiretroviral-naive patients from an ongoing prospective cohort","volume":"31","author":"Boccara","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib120","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002683","article-title":"HIV and hepatitis C-coinfected patients have lower low-density lipoprotein cholesterol despite higher proprotein convertase subtilisin kexin 9 (PCSK9): an apparent \"PCSK9-lipid paradox","volume":"5","author":"Kohli","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib121","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.atherosclerosis.2019.02.015","article-title":"Clinical, behavioral and biomarker predictors of PCSK9 levels in HIV-infected patients naive of statin therapy: a cross-sectional analysis from the Swiss HIV cohort","volume":"284","author":"Gencer","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib122","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000442976","article-title":"Increased plasma PCSK9 levels are associated with reduced endotoxin clearance and the development of acute organ failures during sepsis","volume":"8","author":"Boyd","year":"2016","journal-title":"J Innate Immun"},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib123","doi-asserted-by":"crossref","first-page":"E732","DOI":"10.1210\/jc.2012-4236","article-title":"Plasma PCSK9 is a late biomarker of severity in patients with severe trauma injury","volume":"98","author":"Le Bras","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib124","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1172\/JCI88884","article-title":"Therapeutic approaches targeting inflammation for diabetes and associated cardiovascular risk","volume":"127","author":"Goldfine","year":"2017","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib125","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1210\/jc.2017-00684","article-title":"The effect of PCSK9 loss-of-function variants on the postprandial lipid and apob-lipoprotein response","volume":"102","author":"Ooi","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib126","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","article-title":"Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial","volume":"5","author":"Sabatine","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib127","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1007\/s00125-019-4856-7","article-title":"Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study","volume":"62","author":"Rosenson","year":"2019","journal-title":"Diabetologia"},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib128","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.007402","article-title":"Residual risk of atherosclerotic cardiovascular events in relation to reductions in very-low-density lipoproteins","volume":"6","author":"Lawler","year":"2017","journal-title":"J. Am. Heart. Assoc."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib129","series-title":"Alirocumab and Cardiovascular Outcomes in Patients with Acute Coronary Syndrome (ACS) and Diabetes--PrespeciAed Analyses of ODYSSEY OUTCOMES","author":"Ray","year":"2018"},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib130","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.atherosclerosis.2018.06.871","article-title":"Lipid management in ACS: should we go lower faster?","volume":"275","author":"Gencer","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib131","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.diabet.2017.07.009","article-title":"Circulating PCSK9 levels in acute coronary syndrome: results from the PC-SCA-9 prospective study","volume":"43","author":"Cariou","year":"2017","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib132","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4093\/dmj.2017.0081","article-title":"Serum levels of PCSK9 are associated with coronary angiographic severity in patients with acute coronary syndrome","volume":"42","author":"Bae","year":"2018","journal-title":"Diabetes Metab. J"},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib133","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ijcard.2018.03.081","article-title":"Serum PCSK9 levels predict the occurrence of acute coronary syndromes in patients with severe carotid artery stenosis","volume":"263","author":"Liberale","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib134","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/clc.23112","article-title":"Design of the randomized, placebo-controlled evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial","volume":"41","author":"Koskinas","year":"2018","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib135","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/07853890.2018.1498118","article-title":"Lipid lowering drugs and inflammatory changes: an impact on cardiovascular outcomes?","volume":"50","author":"Ruscica","year":"2018","journal-title":"Ann. Med."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib136","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1177\/2047487318772936","article-title":"Cholesterol and inflammation: the lesser the better in atherothrombosis","volume":"25","author":"Rocha","year":"2018","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib137","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa042378","article-title":"C-reactive protein levels and outcomes after statin therapy","volume":"352","author":"Ridker","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib138","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1161\/CIRCULATIONAHA.115.018381","article-title":"Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT","volume":"132","author":"Bohula","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib139","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1177\/2047487318773384","article-title":"Interplay between hypercholesterolaemia and inflammation in atherosclerosis: translating experimental targets into clinical practice","volume":"25","author":"Tunon","year":"2018","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib140","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/CIRCRESAHA.118.313129","article-title":"Anticytokine agents: targeting interleukin signaling pathways for the treatment of atherothrombosis","volume":"124","author":"Ridker","year":"2019","journal-title":"Circ. Res."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib141","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1093\/eurheartj\/ehy533","article-title":"Associations between very low concentrations of low density lipoprotein cholesterol, high sensitivity C-reactive protein, and health outcomes in the Reasons for Geographical and Racial Differences in Stroke (REGARDS) study","volume":"39","author":"Penson","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib142","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1161\/CIRCULATIONAHA.113.004243","article-title":"C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy","volume":"128","author":"Puri","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib143","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.jcmg.2018.04.015","article-title":"Effects of statins on coronary atherosclerotic plaques: the PARADIGM study","volume":"11","author":"Lee","year":"2018","journal-title":"JACC Cardiovasc. Imag."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib144","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/cvr\/cvy293","article-title":"Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology","volume":"115","author":"Tunon","year":"2019","journal-title":"Cardiovasc. Res."},{"issue":"6","key":"10.1016\/j.atherosclerosis.2019.07.015_bib145","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1177\/2047487318815320","article-title":"Long-term exposure to air pollution raises circulating levels of proprotein convertase subtilisin\/kexin type 9 in obese individuals","volume":"26","author":"Macchi","year":"2019","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib146","doi-asserted-by":"crossref","first-page":"258ra143","DOI":"10.1126\/scitranslmed.3008782","article-title":"PCSK9 is a critical regulator of the innate immune response and septic shock outcome","volume":"6","author":"Walley","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib147","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1194\/jlr.M076844","article-title":"Inhibition of PCSK9 does not improve lipopolysaccharide-induced mortality in mice","volume":"58","author":"Berger","year":"2017","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib148","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11883-018-0718-x","article-title":"Pleiotropic anti-atherosclerotic effects of PCSK9 InhibitorsFrom molecular biology to clinical translation","volume":"20","author":"Karagiannis","year":"2018","journal-title":"Curr. Atheroscler. Rep."},{"key":"10.1016\/j.atherosclerosis.2019.07.015_bib149","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","article-title":"Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial","volume":"36","author":"Cannon","year":"2015","journal-title":"Eur. Heart J."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915019314170?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915019314170?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:40:43Z","timestamp":1758156043000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915019314170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":149,"alternative-id":["S0021915019314170"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.07.015","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PCSK9 inhibition and inflammation: A narrative review","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}